NexImmune (NEXI) AI Stock Analysis

• Market Cap: $139.00
• Dividend Yield: N/A
• Average Volume (3M): 148.00
• Price to Earnings (P/E): ―
• Beta (1Y): 0.66
• Revenue Growth: N/A
• EPS Growth: -412.07%
• Country: US
• Employees: 6
• Sector: Healthcare
• Sector Strength: 55
• Industry: Biotechnology
• EPS (TTM): -244.27
• Shares Outstanding: 1,394,671
• 10 Day Avg. Volume: 0
• 30 Day Avg. Volume: 148
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.18
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.11
• Enterprise Value/Market Cap: -199.76K
• Enterprise Value/Revenue: -4.36
• Enterprise Value/Gross Profit: -18.37
• Enterprise Value/Ebitda: 0.26
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 37 Underperform
• Price Target: ―

NexImmune's overall score reflects significant financial instability and operational inefficiencies. The lack of revenue and consistent losses are major concerns, overshadowing any technical or valuation aspects. The absence of earnings and a dividend yield further diminish its investment appeal.

NexImmune Business Overview & Revenue Model

Company Description

NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.

How the Company Makes Money

NexImmune generates revenue primarily through the development and commercialization of its immunotherapy products. The company is engaged in clinical trials and preclinical research to bring its therapies to market. Revenue streams include potential partnerships and collaborations with larger pharmaceutical companies, licensing agreements, and, eventually, product sales if and when its therapies receive regulatory approval. Additionally, NexImmune may receive milestone payments and royalties based on the success and commercialization of its products developed through collaborations.

NexImmune Financial Statement Overview

Summary

NexImmune faces significant financial challenges, with no revenue and consistent losses indicating strategic changes are needed. Despite low leverage, the low equity ratio and negative return on equity are concerns. The cash flow situation highlights the need for better cash management.

Income Statement

NexImmune has recorded no revenue over the past years, highlighting a significant challenge in generating sales. The gross profit margins are negative, reflecting high costs relative to revenue. The net income has shown volatility with a substantial loss in the recent period, indicating profitability issues. The company's EBIT and EBITDA margins are also negative, indicating operational inefficiencies.

Balance Sheet

NexImmune's balance sheet reveals a low debt-to-equity ratio, suggesting a conservative use of debt. However, the negative return on equity indicates that the company is not generating profits from shareholders' investments. The equity ratio is low due to significant liabilities relative to assets, indicating potential financial instability.

Cash Flow

The cash flow statement shows consistent negative free cash flow, reflecting cash outflows exceeding inflows, which could challenge sustainability without external funding. The operating cash flow to net income ratio is negative, indicating poor cash generation from operations. The company needs to improve cash management to ensure liquidity.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
2.12M	0.00	0.00	0.00	0.00	0.00
	Gross Profit
1.51M	-1.02M	-1.50M	-870.28K	-618.99K	-436.37K
	EBIT
-21.63M	-29.19M	-63.08M	-53.26M	-27.85M	-20.89M
	EBITDA
-16.39M	-28.17M	-61.59M	-52.39M	-27.12M	-20.45M
	Net Income Common Stockholders
-20.62M	-32.34M	514.18M	-51.75M	-31.64M	-20.30M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
2.42M	4.65M	34.64M	81.82M	5.03M	10.14M
	Total Assets
5.86M	8.59M	43.06M	91.03M	11.30M	13.72M
	Total Debt
0.00	68.81K	1.02M	0.00	19.12M	53.63M
	Net Debt
-2.42M	-3.13M	-33.62M	-30.33M	14.09M	44.50M
	Total Liabilities
4.94M	5.08M	10.76M	7.27M	27.06M	3.11M
	Stockholders Equity
920.54K	3.51M	32.30M	83.76M	-15.75M	10.61M
Cash Flow		Free Cash Flow
-66.28M	-31.48M	-52.45M	-48.14M	-27.27M	-20.66M
	Operating Cash Flow
-17.61M	-31.43M	-51.19M	-45.79M	-26.40M	-19.42M
	Investing Cash Flow
-43.88M	-44.49K	50.32M	-53.81M	221.94K	9.42M
	Financing Cash Flow
3.14M	0.00	5.18M	124.89M	22.08M	18.76M

NexImmune Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.10
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NEXI, the sentiment is Negative. The current price of 0.1 is below the 20-day moving average (MA) of 0.10, below the 50-day MA of 0.13, and below the 200-day MA of 0.99, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 39.14 is Neutral, neither overbought nor oversold. The STOCH value of <0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NEXI.

NexImmune Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	54 Neutral	$5.34B	3.27	-45.10%	3.30%	16.80%	0.02%
SCNI	52 Neutral	$1.88M	0.37	138.38%	―	―	―
EVAX	51 Neutral	$3.37M	―	-205.75%	―	2552.29%	60.70%
GRI	45 Neutral	$3.15M	―	-468.00%	―	―	98.55%
NEXI	37 Underperform	$139.00	―		―	―	-412.07%
SLRX	30 Underperform	$1.33M	―	-300.16%	―	―	79.57%
QNRX	25 Underperform	$4.93M	―	-138.80%	―	―	42.26%